Allergic Rhinitis Clinical Trial
Official title:
Demonstration of Therapeutic Equivalence/Non-inferiority as Well as Early Onset of Action of the Novel Water-soluble Budesonide Nasal Spray (Budesolv 10) Compared With Marketed Rhinocort® Aqua 64 in Patients Suffering From Grass Pollen Induced Allergic Rhinitis
Verified date | October 2020 |
Source | Marinomed Biotech AG |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Intranasal corticosteroids are accepted as safe and effective first-line therapy for allergic
rhinitis, especially in treatment of persistent symptoms.
Budesonide, a non-halogenic glucocorticoid, is widely used in the management of inflammatory
mucosal diseases like chronic obstructive pulmonary disease, asthma and allergic rhinitis. It
is a highly fat-soluble substance with low water solubility and is presented as dispersion in
marketed nasal sprays, like Rhinocort aqua 64. The maximum therapeutic efficacy of Rhinocort
aqua is obtained after an application period of 7 to 14 days. In Budesolv, the solubility of
budesonide is considerably increased suggesting that the same therapeutic efficacy can be
reached with a lower dose. Better bioavailability of the dissolved drug promise an earlier
onset of therapeutic efficacy. The current trial is undertaken to demonstrate these two
effects. Subjects suffering from grass pollen allergic rhinitis will be challenged with grass
pollen in a challenge chamber.
Allergic subjects will be treated with two actuations (50 μl) of respective study treatment
into each nostril once daily for 8 days. The total daily budesonide dose will be 40 μg per
subject for Budesolv 10 and 256 μg per subject for Rhinocort® aqua 64. The primary objective
of the study is to show non-inferiority of Budesolv 10 to Rhinocort® aqua 64. On day 8 grass
pollen allergic patients will be challenged with grass pollen over a period of 6 hours and
subjective nasal symptoms (congestion, sneezing, itching, rhinorrhea) as well as objective
symptoms (nasal airflow, nasal secretion) will be assessed every 15 minutes.
The second objective of the trial is to demonstrate an early on-set of therapeutic efficacy
of Budesolv 10 compared to Rhinocort aqua. On day 1, grass pollen allergic patients will be
challenged with grass pollen allergen in the challenge chamber over a period of 6 hours.
After 1 hour 45 minutes, patients will receive their first dosage of the respective nasal
spray treatment. During the 6 hour grass pollen challenge, subjective and objective endpoints
will be measured every 15 minutes.
To eliminate an individual bias based on expectations, the effect and onset of action is also
compared to the effects of a suitable placebo. The same set of study participants will
receive all three interventions in three consecutive treatment periods.
Status | Completed |
Enrollment | 82 |
Est. completion date | April 5, 2019 |
Est. primary completion date | April 5, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria A subject will be eligible for inclusion in this study only if all of the following criteria apply: - Written informed consent obtained before any trial related procedures are performed - Healthy male or female subjects aged 18 years or older - Female subjects of child-bearing potential must have a negative pregnancy test and be willing to practice appropriate contraceptive methods until the end of treatment visit - A documented clinically relevant allergic history of moderate to severe SAR to grass pollen for the previous two years - Subjects exhibit a moderate to severe response to approximately 1500 grass pollen grains/m3 within the first 2 hours in the Vienna Challenge Chamber, which is defined as total nasal symptom score (TNSS) of at least 6 (out of 12) using standard VCC grass pollen allergen mixture. Nasal symptom score is the sum of "nasal congestion", "rhinorrhea", "itchy nose" and "sneezing", each of which have been scored on a categorical scale from 0 to 3. - Positive Skin Prick Test (SPT) response (wheal diameter at least 3 mm larger than diluent control) to grass pollen SPT solutions (standard Allergopharma) at screening or within the last 6 months prior to study start. - Positive serum specific IgE against recombinant major allergen components of the used grass pollen (specific CAP IgE =0.70 kU/L) at screening or within the last 6 months prior to study start. - Patients with a body weight of = 50kg and a body mass index within the range of 19-30kg/m2. - Non-smoking subjects (smoked <10 packs years in their lifetime and had not smoked in the last 6 months) - Asthma patients only if the asthma condition is mild or intermittent, and if those are not treated with steroids - Subject has a forced expiratory volume in 1 second (FEV1) of at least 80% of predicted value (ECCS) at the screening. - Subject is capable of understanding the study procedures and potential risks associated with the study, and voluntarily agrees to participate by giving written informed consent. - Subject is able to adhere to dose and visit schedules. - Subject is able to read, understand and complete questionnaires and diaries. Exclusion Criteria A subject will not be eligible for inclusion in this study if any of the following criteria apply: - Pregnant, lactating or sexually active women with childbearing potential who are not using a medically accepted birth control method (pregnancy to be controlled by a pregnancy dipstick test). - A clinical history of uncontrolled asthma within 3 months prior to screening. - Subjects with asthma requiring treatment with inhaled corticosteroids on a regular basis judged by the investigator. - Previous successful immunotherapy to grass pollen, a grass pollen allergen or a cross-reacting allergen within the past 3 years. - Ongoing treatment with any allergen-specific immunotherapy product. - Subjects with a current oral candidiasis infection or treatment for oral candidiasis during the last 30 days before starting the study. - Subjects with history of tuberculosis. - Subjects with any fungal/viral/bacterial respiratory or systemic infections during the last 30 days. - Symptoms of or treatment for upper respiratory tract infection, acute sinusitis, acute otitis media or other relevant infectious process at randomization. - Clinically relevant nasal polyps, medical history of paranasal sinus surgery and/or medical history of surgery of nasal turbinates judged by the investigator. - Subjects with glaucoma or a family history of glaucoma. - Subjects using any ophthalmic steroids during the last 30 days. - Subjects treated with nasal, inhaled or systemic steroids during the last 30 days. - History of anaphylaxis with cardiorespiratory symptoms (immunotherapy, exercise induced, food allergy, drugs or an idiopathic reaction). - Any clinically relevant chronic disease judged by the investigator. - Systemic disease affecting the immune system judged by the investigator. - Use of an investigational drug within 30 days/5 half-lives of the drug (which ever longest) prior to screening. - History of allergy, hypersensitivity or intolerance to any ingredients of the IMP. - History of alcohol or drug abuse. - Being immediate family of the investigator or trial staff, defined as the investigator's/staff's spouse, parent, child, grandparent or grandchild. - Subjects with previous SAR that has proven unresponsive to steroid therapy. - Subjects treated with leukotriene antagonists (1 month before study start), long-lasting anti-histamines, like cetirizine, fexofenandine, loratadine, desloratadine, hydroxyzine (5 to 10 days before study start), mast cell stablizier (2 weeks before study start) or nasal decongestant (3 days before study start). - Subjects with an acute or chronic sinusitis judged by the investigator. - Subjects with hypersensitivity to corticosteroids judged by the investigator. - Subjects with ocular herpes simplex infections. - Subjects with cataracts and with cataract history. |
Country | Name | City | State |
---|---|---|---|
Austria | Vienna Challenge Chamber | Vienna |
Lead Sponsor | Collaborator |
---|---|
Marinomed Biotech AG |
Austria,
Murdoch RD, Bareille P, Ignar D, Miller SR, Gupta A, Boardley R, Zieglmayer P, Zieglmayer R, Lemel P, Horak F. The improved efficacy of a fixed-dose combination of fluticasone furoate and levocabastine relative to the individual components in the treatment of allergic rhinitis. Clin Exp Allergy. 2015 Aug;45(8):1346-55. doi: 10.1111/cea.12556. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total Nasal Symptom Score | subjective compound score evaluating "nasal congestion", "rhinorrhea", "itchy nose" and "sneezing" from "0" (absent) to "3" (severe). The sum of sub-scores is reported as total nasal symptom score (0 - 12) | 2 - 6 hours of allergen challenge | |
Secondary | Total Ocular Symptom Score | subjective compound score evaluating "ocular itching", "redness", "watery eyes" from "0" (absent) to "3" (severe). The sum of sub-scores is reported as total ocular symptom score (0 - 9) | 2 - 6 hours of allergen challenge | |
Secondary | Total Asthma Symptom Score | subjective compound score evaluating "cough", "wheeze", "dyspnea" from "0" (absent) to "3" (severe). The sum of sub-scores is reported as total asthma symptom score (0 - 9) | 2 - 6 hours of allergen challenge | |
Secondary | Nasal airflow | Rhinomanometry | 0 - 6 hours of allergen challenge | |
Secondary | Nasal secretion | tissue weight | 0 - 6 hours of allergen challenge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05080322 -
Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis
|
Phase 4 | |
Recruiting |
NCT06028490 -
A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis.
|
Phase 2 | |
Completed |
NCT04388358 -
Traditional Chinese Medicine for the Treatment of Perennial Allergic Rhinitis on Gut Microbiota and Immune-modulation
|
N/A | |
Recruiting |
NCT04202263 -
Assessment of Suppression of Cutaneous Allergic Responses and Pruritis by Topical Minocycline
|
Phase 2 | |
Completed |
NCT04078009 -
Standardising Nasal Allergen Challenge in Adult With Hay Fever
|
N/A | |
Completed |
NCT03644680 -
Changes in Adaptive Immune Responses and Effector Cell Responses Upon Nasal Allergen Exposure - a Pilot Study
|
N/A | |
Completed |
NCT04541004 -
Adolescent Mite Allergy Safety Evaluation
|
Phase 3 | |
Recruiting |
NCT05378594 -
HDM and Silver Birch NAC Standardisation
|
N/A | |
Not yet recruiting |
NCT05684380 -
Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)
|
Phase 3 | |
Completed |
NCT02943720 -
ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen
|
Phase 2 | |
Not yet recruiting |
NCT01014325 -
Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy
|
Phase 3 | |
Completed |
NCT02910401 -
Clinical Response to Rhinovirus Challenge
|
Phase 2 | |
Completed |
NCT02556801 -
Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy
|
Phase 2 | |
Not yet recruiting |
NCT02233426 -
Effect of Hypertonic Solutions on Allergic Rhinitis Patients
|
N/A | |
Completed |
NCT02352168 -
Airway Inflammation in Children With Allergic Rhinitis and Intervention
|
N/A | |
Completed |
NCT01946035 -
Alpha-Blockers in Allergic Rhinitis (MAN 01)
|
Phase 4 | |
Completed |
NCT01918956 -
PURETHAL Birch RUSH Study
|
Phase 4 | |
Completed |
NCT01682070 -
SUBLIVAC FIX Phleum Pratense DT/DRF
|
Phase 2 | |
Recruiting |
NCT01454492 -
The Relationship Between Allergic Rhinitis and Geographic Tongue
|
N/A | |
Completed |
NCT01439815 -
An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo
|
Phase 4 |